相关实验视频

Updated: May 5, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

甲状腺眼病患者的再治疗过程的观察性表征

Yuanyuan Chen¹, Taylor Linaburg, Sarah Wang

¹Scheie Eye Institute (YC, TL, SW, TP, PAA, G-sY, CAB, MAT), University of Pennsylvania, Philadelphia, Pennsylvania; Divisions of Neuro-ophthalmology (MAT), Oculoplastics (CAB), and Biostatistics (PAA, G-sY), Kansas Health Science Center, Kansas College of Osteopathic Medicine; and Kansas Health Science Center (GM), Kansas College of Osteopathic Medicine, Kansas, Missouri.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society

|January 9, 2025

概括

甲状腺眼病 (TED) 可以在teprotumumab治疗后重新激活. 重复的teprotumumab治疗有效地管理了重新激活的TED,特别是在以前临床活动得分较高和甲状腺荷尔蒙失调的患者中.

科学领域:

眼科医生眼科眼科
内分泌学在内分泌学.
免疫学免疫学免疫学

背景情况:

甲状腺眼病 (TED) 可能在初始teprotumumab治疗后重新激活.
描述重复治疗过程对于管理反复出现的TED来说至关重要.

研究的目的:

评估TED患者在初始teprotumumab治疗后经历了疾病再激活的治疗策略的疗效和结果.
识别重新激活的预测因素,并比较重新治疗的选择.

主要方法:

一项单中心纵向队列研究跟踪了使用teprotumumab治疗的活跃TED患者.
再激活的定义是由位或临床活动评分 (CAS) 的增加.
在接受第二次teprotumumab疗程的患者和接受静脉注射类固醇治疗的患者之间,重新治疗的结果进行了比较.

主要成果:

26%的患者经历了TED重新激活,平均恢复时间为9个月.
重复的teprotumumab治疗导致平均CAS为0和4毫米的proptosis减少.
静脉注射类固醇治疗导致平均CAS为2和最小的亡减少.
以往较高的CAS和甲状腺激素失调与重新激活有显著的关联.

结论:

在teprotumumab之后,TED的重新激活是可能的,并且对重新治疗有反应.
重复的teprotumumab治疗似乎比IV类固醇更有效地管理重新激活的TED.
长期监测和理解重新激活触发器对于优化治疗策略至关重要.

更多相关视频

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

Mixed Reality Assisted Radical Endoscopic Thyroidectomy

Mixed Reality Assisted Radical Endoscopic Thyroidectomy

Published on: January 31, 2025

相关概念视频

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Hyperthyroidism I: Introduction

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...

Hyperthyroidism II: Pathophysiology

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...

Graves' Disease I: Introduction

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...

Graves Disease II: Pathophysiology

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...

Hypothyroidism II: Pathophysiology

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...